Silvestri, R., Nicolì, V., Gangadharannambiar, P., Crea, F., & Bootman, M. D. (2023). Calcium signalling pathways in prostate cancer initiation and progression. Nature Reviews Urology. https://doi.org/10.1038/s41585-023-00738-x

Article  PubMed  Google Scholar 

Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017). Therapeutic approaches targeting MYC-driven prostate cancer. Genes, 8, 71.

Article  PubMed  PubMed Central  Google Scholar 

Taichman, R. S., Loberg, R. D., Mehra, R., & Pienta, K. J. (2007). The evolving biology and treatment of prostate cancer. The Journal of clinical investigation, 117, 2351–2361. https://doi.org/10.1172/jci31791

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crawford, E. D., Heidenreich, A., Lawrentschuk, N., Tombal, B., Pompeo, A. C. L., Mendoza-Valdes, A., Miller, K., Debruyne, F. M. J., & Klotz, L. (2019). Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate cancer and prostatic diseases, 22, 24–38. https://doi.org/10.1038/s41391-018-0079-0

Article  PubMed  Google Scholar 

Ehsani, M., David, F. O., Baniahmad, A. (2021). Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers. 13. https://doi.org/10.3390/cancers13071534

Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W., & Nevalainen, M. T. (2017). Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget, 8, 3724–3745. https://doi.org/10.18632/oncotarget.12554

Article  PubMed  Google Scholar 

Merkens, L., Sailer, V., Lessel, D., Janzen, E., Greimeier, S., Kirfel, J., Perner, S., Pantel, K., Werner, S., & von Amsberg, G. (2022). Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. Journal of experimental & clinical cancer research : CR, 41, 46. https://doi.org/10.1186/s13046-022-02255-y

Article  CAS  PubMed Central  Google Scholar 

Montironi, R., Cimadamore, A., Lopez-Beltran, A., Scarpelli, M., Aurilio, G., Santoni, M., Massari, F., Cheng, L. (2020). Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 9. https://doi.org/10.3390/cells9051073

Coleman, W. B. (2018). Chapter 25 — Molecular pathogenesis of prostate cancer. In Molecular pathology (Second Edition), Coleman, W.B., Tsongalis, G.J., Eds.; Academic Press. pp. 555–568.

Avkshtol, V., Ruth, K. J., Ross, E. A., Hallman, M. A., Greenberg, R. E., Price, R. A., Jr., Leachman, B., Uzzo, R. G., Ma, C., Chen, D., et al. (2020). Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer. Journal of clinical oncology : Official journal of the American Society of Clinical Oncology, 38, 1676–1684. https://doi.org/10.1200/jco.19.01485

Article  PubMed  Google Scholar 

Hagiwara, M., Fushimi, A., Yamashita, N., Bhattacharya, A., Rajabi, H., Long, M. D., Yasumizu, Y., Oya, M., Liu, S., & Kufe, D. (2021). MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene, 40, 4930–4940. https://doi.org/10.1038/s41388-021-01899-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagiwara, M., Fushimi, A., Bhattacharya, A., Yamashita, N., Morimoto, Y., Oya, M., Withers, H. G., Hu, Q., Liu, T., Liu, S., et al. (2022). MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology, 11, 2029298. https://doi.org/10.1080/2162402x.2022.2029298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, Y., Liu, L., Li, M., Cheng, X., Fang, M., Zeng, Q., & Xu, Y. (2019). The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis. Biochimica et biophysica acta. Gene Regulatory Mechanisms, 1862, 834–845. https://doi.org/10.1016/j.bbagrm.2019.05.005

Article  CAS  PubMed  Google Scholar 

Zhao, D., Zhang, M., Huang, S., Liu, Q., Zhu, S., Li, Y., Jiang, W., Kiss, D. L., Cao, Q., Zhang, L., et al. (2022). CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. Nucleic Acids Research, 50, 12186–12201. https://doi.org/10.1093/nar/gkac1090

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2019). Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. The Journal of clinical investigation, 129, 759–773. https://doi.org/10.1172/jci123557

Article  PubMed  PubMed Central  Google Scholar 

Rajwa, P., Quhal, F., Pradere, B., Gandaglia, G., Ploussard, G., Leapman, M. S., Gore, J. L., Paradysz, A., Tilki, D., Merseburger, A. S., et al. (2023). Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 20, 205–216. https://doi.org/10.1038/s41585-022-00680-4

Article  CAS  PubMed  Google Scholar 

Loeb, S., & Giri, V. N. (2021). Clinical implications of germline testing in newly diagnosed prostate cancer. European urology oncology, 4, 1–9. https://doi.org/10.1016/j.euo.2020.11.011

Article  PubMed  Google Scholar 

Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A., Aljadeed, R., Alsowaida, Y., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. The Prostate, 79, 880–895. https://doi.org/10.1002/pros.23795

Article  CAS  PubMed  Google Scholar 

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016). Inherited DNA-repair gene mutations in men with metastatic prostate cancer. The New England Journal of Medicine, 375, 443–453. https://doi.org/10.1056/NEJMoa1603144

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shore, N., Oliver, L., Shui, I., Gayle, A., Wong, O. Y., Kim, J., Payne, S., Amin, S., & Ghate, S. (2021). Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. The Journal of urology, 205, 977–986. https://doi.org/10.1097/ju.0000000000001570

Article  PubMed  Google Scholar 

Wang, Z., Wang, T., Hong, D., Dong, B., Wang, Y., Huang, H., Zhang, W., Lian, B., Ji, B., Shi, H., et al. (2022). Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer. iScience, 25, 104576. https://doi.org/10.1016/j.isci.2022.104576

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Lv, S., Wu, Z., Luo, M., Zhang, Y., Zhang, J., Pascal, L. E., Wang, Z., & Wei, Q. (2022). Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell Death & Disease, 13, 754. https://doi.org/10.1038/s41419-022-05182-0

Article  CAS  Google Scholar 

Tang, D. G. (2022). Understanding and targeting prostate cancer cell heterogeneity and plasticity. Seminars in Cancer Biology, 82, 68–93. https://doi.org/10.1016/j.semcancer.2021.11.001

Article  CAS  PubMed  Google Scholar 

Cyrta, J., Prandi, D., Arora, A., Hovelson, D. H., Sboner, A., Rodriguez, A., Fedrizzi, T., Beltran, H., Robinson, D. R., Gopalan, A., et al. (2022). Comparative genomics of primary prostate cancer and paired metastases: Insights from 12 molecular case studies. The Journal of pathology, 257, 274–284. https://doi.org/10.1002/path.5887

Article  CAS  PubMed  Google Scholar 

Sun, G., Ma, S., Zheng, Z., Wang, X., Chen, S., Chang, T., Liang, Z., Jiang, Y., Xu, S., & Liu, R. (2022). Multi-omics analysis of expression and prognostic value of NSUN members in prostate cancer. Frontiers in Oncology, 12, 965571. https://doi.org/10.3389/fonc.2022.965571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia, D., Zhou, Z., Kwon, O. J., Zhang, L., Wei, X., Zhang, Y., Yi, M., Roudier, M. P., Regier, M. C., Dumpit, R., et al. (2022). Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. Nature Communications, 13, 6828. https://doi.org/10.1038/s41467-022-34665-z

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Chang, M., He, Y., Liu, C., Lin, R., Huang, X., Liang, D., Zhang, J., & Lu, Y. (2022). Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8(+) T cell infiltration. International Journal of Biological Sciences, 18, 6035–6051. https://doi.org/10.7150/ijbs.76573

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding, L., Wang, R., Zheng, Q., Shen, D., Wang, H., Lu, Z., Luo, W., Xie, H., Ren, L., Jiang, M., et al. (2022). circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. Journal of Experimental & Clinical Cancer Research : CR, 41, 187. https://doi.org/10.1186/s13046-022-02391-5

Article  CAS  PubMed Central  Google Scholar 

Li, Z., Li, B., Yu, H., Wang, P., Wang, W., Hou, P., Li, M., Chu, S., Zheng, J., Mao, L., et al. (2022). DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability. Oncogene, 41, 3991–4002. https://doi.org/10.1038/s41388-022-02404-9

Article  CAS  PubMed  Google Scholar 

Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575, 299–309. https://doi.org/10.1038/s41586-019-1730-1

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Goldie, J. H., & Coldman, A. J. (1984). The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Research, 44, 3643–3653.

CAS  PubMed  Google Scholar 

Fisher, B., Slack, N. H., & Bross, I. D. (1969). Cancer of the breast: Size of neoplasm and prognosis. Cancer, 24, 1071–1080. https://doi.org/10.1002/1097-0142(196911)24:5%3c1071::aid-cncr2820240533%3e3.0.co;2-h

Article  CAS  PubMed  Google Scholar 

Skipper, H. E.,